Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Legend Biotech Corp ADR (NQ: LEGN )

27.12 +0.41 (+1.52%)
Streaming Delayed Price Updated: 2:17 PM EDT, Apr 21, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 142,048
Open 26.55
Bid (Size) 27.02 (60)
Ask (Size) 27.23 (6)
Prev. Close 26.72
Today's Range 26.42 - 27.53
52wk Range 23.41 - 43.24
Shares Outstanding 266,010,256
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Legend Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Business Update
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other... 
From Business Wire News Releases
Legend Biotech Announces Fourth Quarter and Full-Year 2020 Earnings Conference Call
Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other... 
From Business Wire News Releases

Performance

YTD
-3.09%
-3.09%
1 Month
+2.13%
+2.13%
3 Month
-8.05%
-8.05%
6 Month
-9.07%
-9.07%
1 Year
-26.69%
-26.69%

More News

Read More
Legend Biotech Announces Preliminary Results for the Year Ended December 31, 2020
From Business Wire News Releases
Legend Biotech Announces BCMA CAR-T Therapy Cilta-cel Accepted for Accelerated Assessment in Europe for the Treatment of Relapsed and/or Refractory Multiple Myeloma
From Business Wire News Releases
Legend Biotech Announces Initiation of Rolling Submission of Biologics License Application to U.S. FDA Seeking Approval of BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed and/or Refractory
From Business Wire News Releases
Legend Biotech to Participate in the 39th Annual J.P. Morgan Healthcare Conference
From Business Wire News Releases
Legend Biotech Added to the NASDAQ Biotechnology Index
From Business Wire News Releases
Legend Biotech Announces FDA Clearance of the IND for LB1901, an Investigational Autologous Anti-CD4 CAR-T Therapy for Relapsed or Refractory T-Cell Lymphoma
From Business Wire News Releases
Week in Review: Beijing's Jacobio Completes $174 Million Hong Kong IPO
From ChinaBio® Today
Week In Review: Beijing's Jacobio Completes $174 Million Hong Kong IPO
Tags Healthcare Stocks / Equities Pharma/Biotech
From Blogs - TalkMarkets
Legend Starts Submission for US Approval of BCMA CAR-T Therapy
From ChinaBio® Today
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.